Support our Foundation of Myology project
ARGX-119-2302
A phase 1b, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy of ARGX-119 in adult participants with congenital myasthenic syndromes related to DOK7 gene mutations.